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Objective: To record the antibiotic resistance of community acquired uropathogens over
a period of 24 months (May 2011–April 2012).
Methods: Urine samples from patients of outpatient department (OPD) were used for
isolating urinary tract infection (UTI)-causing bacteria that were cultured on suitable
selective media and identiﬁed by biochemical tests. Their antibiograms were ascertained
by Kirby–Bauer's disc diffusion method, using 17 antibiotics of 5 different classes.
Results: From 2137 urine samples 1332 strains of pathogenic bacteria belonging to 11
species were isolated. Two Gram-positives, Staphylococcus aureus and Enterococcus
faecalis and nine Gram-negatives, Acinetobacter baumannii, Citrobacter sp., Escherichia
coli, Enterobacter aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mir-
abilis, Proteus vulgaris and Pseudomonas aeruginosa were isolated. Both Staphylo-
coccus aureus and Enterococcus faecalis were vancomycin resistant, and resistant-strains
of all pathogens increased in each 6-month period of study. Particularly, all Gram-
negatives were resistant to nitrofurantoin and co-trimoxazole, the most preferred antibi-
otics of empiric therapy for UTI, but were moderately resistant to gentamicin, ampicillin,
amoxyclav, oﬂoxacin and gatiﬂoxacin. Most Gram-negatives produced extended spec-
trum b-lactamase.
Conclusions: It was concluded that periodic surveillance of pathogens is an essential
corollary in effective health management in any country, as empiric therapy is a common/
essential practice in effective clinical management.1. Introduction
Due to the lack of a rational antibiotic policy in clinical
medicine, antibiotics are misused more often than not in
developing countries and less often than not in developed
countries, which lead to the increased emergence of multidrug
resistant (MDR) strains of pathogenic bacteria and even of
commensals. Not astonishingly, the MDR strains/serotypes of
commensals too cause many a disease similar to well-known
pathogenic bacteria, and have been spreading alike both in
community and hospital settings[1], unseen in the pre-antibiotic
era. For example, from clonal nexuses of the Gram-positive(GP), Staphylococcus aureus (S. aureus), the well-known
commensal of soft tissues of human body, the methicillin
resistant S. aureus (MRSA) has emerged independently at
diverse geographic zones and have escalated to all types of
communities, which has been regarded as the ghoulish and
intractable superbug in the health domain for its aggrandizement
of multiple resistances, worldwide[2]. Such S. aureus strains,
marked as MDR-MRSA, are seen as the marauding silently
violent pathogen of all types of wounds (surgical sites, burns, cut
injuries and bedsores, etc.), as well as in urinary tract, causing
initially controllable bacteriuria, and fatal bacteremia ulti-
mately[3,4], if any urinary tract infection (UTI) is neglected.
Indeed, when S. aureus was simply a commensal without any
drug resistance character, never it caused any clinical
exasperation. Further, the upper respiratory tract infection and
UTI are commonplaces of initial infection at any rural
community[5–7]. Moreover as reported often, several species of
Gram-negative (GN) bacteria insinuate the urinary tract apart
from MRSA; for instance, MDR Pseudomonas aeruginosa
(P. aeruginosa) avatars were the notoriously active uropathogen,.
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others too[8,9]. Particularly, spread of any MDR bacterial strain is
so fast that, a patient with any morbidity—be it may non-
infectious, from a community intending to attend the outpa-
tient department (OPD) of a hospital, carries insidiously one or
other MDR pathogen, causing a nosocomial spread. Such
spreads too occur at frenetic pace in less-unhygienic condi-
tions[7,10,11], causing an avalanche of MDR strains of a torrent of
bacteria sometimes against whom, particular antibiotics were
never used to bacteria that were seen as multi resistant[2,12]. To
state curtly, the spate of MDR bacteria have caused a complex
picture of infection dynamics of any community or hospital
today[13], challenging the cleanly totem of any hospital, even
of a developed country.
Resistance for the ﬁrst line antibiotics creates circumspection
in the mind of a clinician for treating any infection empirically.
Obviously, high level antibiotics such as those belonging to
second or third generation cephalosporin or any other advanced
carbapenem, cefuroxime or imipenem or a few more are used
empirically for the prophylaxis of UTI for success[14].
Logistically, one from a higher generation antibiotic groups
should not be prescribed initially, without the availability of
the culture report of a clinical sample; on the other hand, if
the empiric therapy fails in an UTI case, further complications,
cystitis, urethritis, pyelonephritis and a grievous bacteremia
thereafter would occur in the next few days ultimately, leading
to fatality due to use of an older/lowbrow antibiotic in face of
an unknown antibiotic resistance in the causative bacterium. It
would not be out of place to cite here that the mortality rate
from bacteremia was approximately 81% in 1973[15,16], and
50% in 2006 due to MDR P. aeruginosa strains[17], a potent
UTI bacterium. Moreover, it has been recorded that one in
every ﬁve women picked up UTI and 95% of UTI causing
organisms developed infectious complications at the notch of
urethra, leading to cystitis. In sexually active women, recurrent
UTI is reported to be more frequent. Young, adolescent girls
also develop cystitis or bladder infection by UTI causing
organisms[18]. UTIs are common in patients with diabetes
mellitus (DM) too, as this condition alters the urinogenital
system, letting space/niche for the survival of pathogenic
bacteria.
Indeed, without any functional abnormality in the urinary
tract, uncomplicated UTI occurs in patients in around 6 days for
the development of symptoms, and 2.4 days additionally for
comorbidities from initial cystitis leading to restricted activ-
ities[19–21], as in about 95% of all systematic UTI infections,
cystitis is the most common initial comorbidity[22]. Thus, in the
case of an UTI patient, the empiric therapy is a must, as at
least 3 or 4 days are needed for the antibiotic proﬁling of
bacteria from the urine sample. Another inherent problem
while addressing an UTI episode with a newer/latest
generation of antibiotic is the expression of acute
gastroenteritis or maculopapular rash, which could be transient
as side effects in elderly people, or acute side effects in
children[23]. To overcome these problems, deliberate
surveillances of infection scenario at several zones are needed,
when considered from angles of public health in a community,
as MDR strains of bacteria evolve and spread far, wide and
faster than imagined[24].
With symptomatic UTI, a patient may have fever  38 C
with chills, headache, vomiting, or burning pain, frequency or
urgency during urination, change of colour of urine or new ﬂankor suprapubic pain and tenderness[10]. Obviously, these
symptoms are gathered from a patient before the urine sample
is given for culturing or any antibiotic is administered,
empirically. In addition, a patient may have signiﬁcant
deterioration in activities required to carry out a normal life or
the cognitive status. Bloody urine, foul smell or an amount of
sediment are often reported from urine of symptomatic cases.
However, these cited symptoms are usually seen with patients,
who had a defective urine analysis with a negative result[25]; it
is the determinative cause of acute UTI complications. In
addition, the test for pyuria is also considered as a criterion
for UTI, but it is neither relatively predictive for bacteriuria
nor is a categorical symptom for UTI of a woman in a
community[25]. The prevalence of asymptomatic bacteriuria is
high in elderly patients[26], but that also is not an independent
predictor of mortality, notwithstanding its progress to
bacteremia, because a timely effective treatment with certain
newer generation of antibiotics has been associated with
control[27,28].
The alternate therapy for uncomplicated UTI includes nitro-
furantoin or fosfomycin, routinely[29]. In vitro studies on
antimicrobial resistant patterns with routinely used antibiotics
for urinary isolates of Escherichia coli (E. coli) were many[30].
However, the emergence of MDR strains resistant to newer
and potent antimicrobials has become commonplace making
therapeutic options limiting to antimicrobials, carbapenems,
colistin and fosfomycin. An updated knowledge on
antimicrobial susceptibility of MDR UTI pathogens is of
prime importance for thwart of issues of public health from
UTI. This study elucidates that Enterobacteriaceae members
are the predominant UTI causing pathogens, followed by GP
cocci.
Diabetes mellitus (DM) has been a major source of clinical
problems[31,32]. It is consensus that, individuals with DM have
increased risk of most severe community acquired infections—
respiratory tract infections primarily, followed by UTI[33].
However, when local factors of spread of infections could be
identiﬁed and quantiﬁed under an effective medical surveillance
system for this class of pathogens, due steps could be initiated
for the abatement of pathogen spreads, as the continual wave of
the emergence of armoured MDR uropathogens create a
frightening or rather an exacerbating state of affairs in clinical
managements, especially in females. The present study records
community-acquired (CA) accounts of antibiotic resistance of
egregious strains of a cohort of uropathogens, isolated from
clinical samples of patients attending the OPD of a hospital, over
a period of 24 months the most common, rather notorious MDR
pathogens. This study gives information on the antibiograms of
11 strains of bacteria in a typical Indian teaching hospital, an
exhaustive study rarely conducted from clinical samples OPD
patients.
This Indian record should strengthen the epidemiological
database of this vast sub-tropical country and would help ﬁxing
facilitation of quality improvement in clinical management at the
community sector for the reduction in the cost of hospitalization,
as well as in the reduction of morbidity and mortality in the
women section due to both GP and GN MDR uropathogens. The
pharmacy world too is anticipated to be beneﬁtted by this and
similar surveillance studies on subtle MDR pathogens all over,
for an exactitude in the empiric therapy for the control of uro-
pathogens. Moreover, the empiric therapy options for this dis-
ease would be well substantiated by this surveillance with a
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prevent, a priory, the use of some lowbrow antibiotic regimen,
for the desperate lady-patients in an acute state of morbidity,
dabbling with an UTI from MDR bacteria that might lead to the
terminal bacteremia, by blood stream infection initiated through
the UTI problem at least in immune-compromised ones.
2. Materials and methods
2.1. Isolation and identiﬁcation of pathogenic bacteria
From patients attending OPD of IMS and Sum Hospital,
2137 urine samples yielded 1332 strains of pathogenic bacteria
belonging to 11 species (two GP and nine GN bacteria) during
the span of 24 months (May 2011–April 2013). All isolated
bacterial strains [S. aureus, Enterococcus faecalis
(E. faecalis), Acinetobacter baumannii (A. baumannii), Cit-
robacter sp., E. coli, Enterobacter aerogenes (E. aerogenes),
Klebsiella oxytoca (K. oxytoca), Klebsiella pneumoniae
(K. pneumoniae), Proteus mirabilis (P. mirabilis), Proteus
vulgaris (P. vulgaris) and P. aeruginosa] were identiﬁed by
standard biochemical tests and were maintained as axenic
cultures in suitable media. Microbial Type Culture Collection
(MTCC) strain of each bacterium was used as reference con-
trols during identiﬁcation.
2.1.1. Puriﬁcation of GP cocci
For pure-cultures of GP cocci, catalase and coagulase tests
were performed. The catalase test was done with a drop of 3%
H2O2 that caused effervescence indicating the presence of
catalase enzyme. For the coagulase test, a lump of a test or-
ganism was emulsiﬁed with a drop of normal saline water
(0.89%) and a drop of human blood serum was added to the
suspension; clumping of cells was observed within 10 s, for
conﬁrmation of the presence of bound coagulase enzyme. When
a sample of GP cocci responded positively to both catalase and
coagulase tests, it was conﬁrmed as S. aureus. Further, catalase
negative, alpha-haemolytic (partial or green haemolysis of
erythrocytes) colonies were subjected to bile-esculin test. The
bile-esculin medium contains esculin and peptone for nutrition,
and bile to inhibit growth of GP bacteria, other than Group D
streptococci or enterococci. Ferric citrate was added as a colour-
indicator. Organisms, which split esculin molecules and use the
liberated glucose to supply energy, release esculin into the me-
dium. The free esculin reacts with ferric citrate in the medium to
form a phenol–iron complex, which turns the agar-slant from
dark brown to black. An agar-slant that was more than half
darkened within 48 h of incubation was bile-esculin positive, for
the conﬁrmation of E. faecalis; but the alternative non-darkening
of the agar was taken as the negative result[34].
2.1.2. Puriﬁcation of GN bacilli
For pure-cultures of GN bacilli, the following tests were
done in succession along with the catalase test. (1) Oxidase test:
A bacterial colony was rubbed onto a ﬁlter paper, impregnated
with tetramethyl-p-phenylenediamine dihydrochloride and the
dye indophenols; the zone of the ﬁlter paper turns blue/purple in
the positive result, while the negative result is with no change of
colour. (2) Indole test: To an aliquot of 5 mL 48 h old grown
culture (test culture), an aliquot of 0.5 mL of Kovac's reagent (p-
dimethylaminobenzaldehyde, isoamyl alcohol and HCl) wasadded. A formation of a cherry-red or purple-red ring at the
interface of the broth culture and the reagent indicated the indole
production from tryptophan by the test culture. (3) Methyl red
test (MR test): An aliquot of 5 mL sterile MRVP broth (peptone
7 g, glucose 5 g, potassium phosphate 5 g, pH 6.9, inoculated
and incubated for 48 h at 37 C) was prepared. To this culture,
ﬁve drops of methyl red solution were added as an indicator. If
the total solution turned red, the test was taken as positive for
the formation of organic acids as products. (4) Voges–Proskauer
test (VP test): To an aliquot of 5 mL sterile MRVP broth, a
loopful of the test culture was inoculated and the mixture was
incubated for 48 h at 37 C. To this culture tube, 10 drops of VP
I reagent (5% a-napthol, in absolute alcohol) and 2–3 drops of
VP II reagent (40% KOH solution) were added and the mixture
was allowed to stand for 15–20 min for the reaction to complete.
The positive result was the appearance of red colour of the
mixture, i.e., production of a neutral product, acetoin from the
fermentation of glucose by the organism, and alternately yellow
colour production indicated the negative result. (5) Citrate test:
The test culture was inoculated onto a slant of Simon citrate
agar that was incubated for 48 h at 37 C. The change of colour
of agar from green to blue indicated that organism used citrate
as the sole source of carbon. (6) Urease test: The test organism
was inoculated onto a slant of Christensen's urea agar (peptone,
glucose, sodium chloride, mono-potassium phosphate, urea,
phenol red, distilled water, and at pH 6.8). The hydrolysis of
urea yielding ammonia gas increases the pH that changes the
colour of the medium from off-white to pink/orange, the posi-
tive result. (7)Triple-sugar-iron test (TSI test): Two or three
drops of test broth culture were inoculated on TSI-agar slant and
subsequently, a stab was made up to the butt of the slant. The
tube was incubated at 37 C for 48 h; the black colour
appearance indicated the H2S production. (8) Nitrate test: An
aliquot of 5 mL of nitrite broth (peptone 5 g, beef-extract 3 g,
KNO3 1 g and distilled water 1000 mL) was inoculated with 1
drop of 24 h old broth test culture and was incubated for 48 h at
37 C. From the development of red colour within 30 s of
adding a few drops of the reagent A (a-napthol 5 g in 1000 mL
of 30% acetic acid) and reagent B (sulphanilic acid 5 g in
1000 mL acetic acid) the positive result was inferred. No colour
change suggested the negative result[34]. MTCC strain of each
GP or GN bacterium was used as the reference control in
each biochemical test.
2.2. Antibiotic susceptibility test
All bacterial strains including the standard MTCC strains of
each bacterium were subjected to antibiotic sensitivity tests by
the Kirby–Bauer's method/disc diffusion method, using a 4 mm
thick Mueller–Hinton agar (HiMedia, Mumbai) medium[9]. An
aliquot of 0.1 mL of 0.5 McFarland equivalents,
approximately from an exponentially growing culture was
spread on agar for the development of lawn of a strain of a
bacterium at 37 C in a BOD incubator (Remi CIM-12S).
Further, on the lawn-agar of each plate, 8 high potency antibi-
otic discs (HiMedia) of 17 prescribed antibiotics of 5 different
groups were placed, individually at equal distances from one
another. Plates were incubated for 18 h at 37 C and were
examined for size-measurements of zones of inhibition around
each disc, following the standard antibiotic susceptibility test
chart of Clinical Laboratory Standard Institute (CLSI)
guidelines[35].
Figure 1. Pseudomonas aeruginosa on nutrient agar.
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From OPD, a total of 2137 urine samples yielded 1332
strains of pathogens belonging to 11 species with two GP and
nine GN bacteria, during the span of 24 months. In total, there
were 157 strains of E. faecalis, 201 strains of S. aureus, 103
strains of A. baumannii, 68 strains of Citrobacter sp., 98 strains
of E. aerogenes, 253 strains of E. coli, 146 strains of
K. pneumoniae, 60 strains of K. oxytoca, 90 strains of
P. mirabilis, 58 strains of P. vulgaris and 98 strains of
P. aeruginosa. Thus, E. coli was the maximally isolated UTI
causing bacterium, followed by, S. aureus, E. faecalis,
K. pneumoniae, P. aeruginosa, A. baumannii, E. aerogenes,
P. mirabilis, P. vulgaris, and K. oxytoca (Table 1).
GP bacteria as medium to large, smooth, entire, slightly
raised, creamy yellow, green/beta-haemolytic colonies on blood
agar, positive to catalase and coagulase tests were conﬁrmed to
be S. aureus. Further, bile-esculin producing colonies, negative
to catalase and coagulase tests were taken as E. faecalis, which
produced grayish, round, small colonies without any haemolytic
zones on blood agar. Further, the GN bacterium, A. baumannii
was identiﬁed on colony characteristics on nutrient agar (NA),
MacConkey (MC) agar and cysteine-lactose-electrolyte-deﬁcient
(CLED) agar and with results obtained from adopted biochem-
ical procedures: it grew as colourless, smooth, opaque, raised
and pinpoint colonies on NA, but as colourless, smooth, opaque,
raised and non-lactose-fermenting (NLF) colonies on MC agar;
it was found positive to catalase, VP and citrate tests, whereas
negative to oxidase, indole, MR and nitrate tests. Similarly,
Citrobacter sp. was identiﬁed by its colony characteristics on
MC agar and results obtained from the nine biochemical tests; it
produced light pink-coloured late-lactose-fermenting (LLF)
colonies after an 48 h of incubation on MC agar; particularly, it
was found positive to catalase, MR, citrate and nitrate tests,
whereas negative to oxidase, indole, VP and urease tests. On the
TSI, the bacterium produced both acid and H2S gas during
growth. Again, E. aerogenes produced white convex with
gamma-haemolytic colonies on blood agar, and lactose fer-
menting (LF), and mucoid colonies on MC agar. From,
biochemical tests, E. aerogenes was seen positive to catalase,
citrate, VP and nitrate tests, whereas negative to oxidase, indole,
MR and urease tests. On a TSI slant, it produced acid in slant
and gas production in the butt. E. coli produced ﬂat dry, irregular
colonies on NA; LF, ﬂat, dry, pink and irregular colonies on MCTable 1
Bacteria isolated from a total of 2137 urine samples of OPD patients.
Bacteria May–October 2011 November–April 2012
E. faecalisa 25 45
S. aureusa 55 44
A. baumannii 25 28
Citrobacter sp. 14 21
E. aerogenes 21 28
E. coli 72 54
K. oxytoca 10 17
K. pneumoniae 38 37
P. mirabilis 23 24
P. vulgaris 19 15
P. aeruginosa 35 28
Grand total 337 341
a : Gram-positive bacteria, while the rest were Gram-negative bacteria.agar; purple coloured, ﬂat, dry, irregular colonies, with metallic
green colour on eosin methylene blue agar were noted by E. coli,
but translucent blue colonies on CLED agar were evident.
Further, E. coli was positive to catalase, indole, MR and nitrate
tests, whereas found negative to oxidase, VP, citrate and urease
tests; on the TSI test, it produced acid both in slant and butt of
with gas. Both, K. pneumoniae and K. oxytoca colonies on
CLED agar were yellow and mucoid, whereas they produced
LF, pink-coloured, mucoid colonies on MC agar. K. pneumoniae
was found positive to catalase, VP, citrate and urease and nitrate
tests, whereas it was negative to indole, MR and oxidase tests.
On the TSI test, K. pneumoniae strains produced acids both in
butt and slant along with gas production. K. oxytoca was found
positive to the indole test, whereas the rest other test results were
similar to those of K. pneumoniae. Similarly, both P. mirabilis
and P. vulgaris had swarming and beta-haemolytic colonies on
blood agar and translucent blue colonies on CLED agar. Further,
P. mirabilis was found positive to catalase, MR, citrate and
urease and nitrate tests, whereas it was negative to indole, VP,
and oxidase tests. On the TSI test, P. mirabilis strains produced
acids in both butt and slant along with H2S gas. P. vulgaris was
found positive to indole test, whereas the rest other results were
similar to those of P. mirabilis. P. aeruginosa produced large,
irregular, opaque colonies with blue-green pigment on NA
(Figure 1); it was found positive to catalase, oxidase, urease and
nitrate test, whereas negative to indole, MR and VP tests
(Tables 2 and 3).May–October 2012 November 2012–April 2013 Total
45 42 157
53 49 201
21 29 103
15 18 68
23 26 98
68 59 253
15 18 60
33 38 146
15 28 90
13 11 58
17 18 98
318 336 1332
Table 2
Media used for isolation and maintenance pathogenic bacteria from urine samples and their colony characteristics.
Bacterium MTCC strain number Media used Colony characteristics
E. faecalis 439 Blood agar Grey coloured, round, gamma hemolytic colonies
S. aureus 7443 Blood agar Medium to large, smooth, entire, slightly raised, creamy yellow, with
green/beta hemolytic colonies
Nutrient agar As above without hemolytic activity
A. baumannii 1425 Nutrient agar Colourless smooth, opaque, raised and pinpoint
MacConkey agar Colourless smooth, opaque, raised, NLF
CLED agar Blue coloured opaque raised NLF
Citrobacter sp. 1658 MacConkey agar Late LF light pink after 48 h
E. aerogenes 2990 Blood agar White convex with gamma-hemolysis
MacConkey agar LF, mucoid
E. coli 443 Nutrient agar Flat dry, irregular
MC agar LF, ﬂat dry pink, irregular
EMB agar Purple coloured, ﬂat dry, irregular colonies, with metallic green colour.
Blood agar Swarms on blood agar with beta-hemolysis
CLED agar Translucent blue
K. oxytoca 2275 MacConkey agar LF, pink, mucoid
CLED agar Yellow mucoid
K. pneumoniae 4031 MC agar LF, pink, mucoid
CLED agar Yellow mucoid
P. mirabilis NA MacConkey agar LLF light pink after 48 h
Blood agar Swarms on blood agar with beta-hemolysis
CLED agar Translucent blue
P. vulgaris 1771 Blood agar Swarms on blood agar with beta-hemolysis
CLED agar Translucent blue
P. aeruginosa 1688 Nutrient agar Large, irregular opaque with bluish green pigment
MTCC: Microbial type culture collection; CLED: Cysteine lactose electrolyte deﬁcient; LF: Lactose fermenting; NLF: Non-lactose fermenting; NA:
Not available.
Table 3
Biochemical identiﬁcation of the isolated Gram-positive and Gram-negative bacteria.
Bacteria Catalase Oxidase Coagulase Indole MR VP Citrate Urease TSI Nitrate Bile esculin
E. faecalis − Nd − Nd Nd Nd Nd Nd Nd Nd +
S. aureus + Nd + Nd Nd Nd Nd Nd Nd Nd Nd
A. baumannii + − Nd − − + + V Nd − Nd
Citrobacter sp. + − Nd − + − + − A/A H2S + Nd
E. aerogenes + − Nd − − + + − A/A + Nd
E. coli + − Nd + + − − − A/AG + Nd
K. oxytoca + − Nd + − + + + A/AG + Nd
K. pneumoniae + − Nd − − + + + A/AG + Nd
P. mirabilis + − Nd − + − + + K/A H2S + Nd
P. vulgaris + − Nd + + − + + K/A H2S + Nd
P. aeruginosa + + Nd − − − + + Nd + Nd
MR: Methyl red test; VP: Voges–Proskauer test; TSI: Triple sugar iron test; V: Variable; A/A: Acid in slant and butt; A/AG H2S: Acid in slant and butt
with H2S gas production; A/AG: Acid in slant and butt with gas production; K/A H2S: Alkali in slant and butt with H2S gas production; Nd: Not
done; +: positive; −: Negative.
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sensitivity tests with 17 antibiotics used, in each 6-month period.
Three aminoglycoside antibiotics, amikacin (30 mg/disc),
gentamicin (10 mg/disc) and netilmicin (30 mg/disc) were
moderately resistant to eleven species of pathogens used, in
ranges, 27–76% of 157 strains of E. faecalis, 31–79% of 201
strains of S. aureus, 25–71% of 103 strains of A. baumannii, 19–
71% of 68 strains of Citrobacter sp., 36–78% of 98 strains of
E. aerogenes, 61–81% of 253 strains of E. coli, 45–65% of 60
strains of K. oxytoca, 66–79% of 146 strains of K. pneumoniae,
63–89% of 90 strains of P. mirabilis, 61–71% of 58 strains of
P. vulgaris, and 66–86% of 98 strains of P. aeruginosa. Among
these three antibiotics, gentamicin was recorded to be more
resistant to these pathogens (Table 4).
Similarly, percentages of resistance patterns of isolated two
GP bacteria with ﬁve antibiotics of the b-lactam group aredetailed (Table 5); resistance patterns were in ranges: 52–74% of
157 strains of E. faecalis, 61–82% of 201 strains of S. aureus.
Likewise, GN bacteria were tested for four b-lactams only, with
resistance patterns as given: 47–77% of 103 strains of
A. baumannii, 52–71% of 68 strains of Citrobacter sp., 52–81%
of 98 strains of E. aerogenes, 51–89% of 253 strains of E. coli,
58–81 % of 60 strains of K. oxytoca, 54–83% of 146 strains of
K. pneumoniae, 22–41% of 90 strains of P. mirabilis, 34–48%
of 58 strains of P. vulgaris, and 41–75 % of 98 strains of
P. aeruginosa. For GN bacteria, antibiotics were resistant in the
order: ampicillin > amoxyclav > piperacillin/tazobactam. But
with GP bacteria such an order would be:
amoxyclav > ampicillin > oxacillin > piperacillin/tazobactam
(Table 5).
Further, resistance-percent values of UTI-bacteria to cepha-
losporin antibiotics (cefepime, ceftazidime and cefuroxime) in
Table 4
Percentage of resistance of all clinically isolated bacteria to three antibiotics of aminoglycoside group.
Bacterium Amikacin (30 mg/disc) Gentamicin (10 mg/disc) Tobramycin (10 mg/disc)
I II III IV I II III IV I II III IV
E. faecalis 55 67 76 64 47 56 59 54 27 34 41 39
S. aureus 69 76 79 71 57 59 56 58 31 49 56 54
A. baumannii 57 68 71 63 54 61 63 65 25 31 36 38
Citrobacter sp. 39 56 71 69 61 59 67 68 19 25 29 37
E. aerogenes 69 78 77 73 48 51 57 68 36 40 41 41
E. coli 74 76 81 79 76 79 80 78 61 67 65 69
K. oxytoca 45 53 61 65 45 54 57 61 63 64 61 63
K. pneumoniae 66 76 79 79 67 69 67 66 66 78 77 75
P. mirabilis 63 69 78 74 89 67 66 69 87 71 76 75
P. vulgaris 62 69 67 70 69 67 71 70 66 67 61 65
P. aeruginosa 74 77 76 72 86 77 67 68 76 68 66 67
I: May–October 2011; II: November 2011–April 2012; III: May 2012–October 2012; IV: November 2012–April 2013.
Table 5
Percentage of resistance of all clinically isolated bacteria to four antibiotics of b-lactam group.
Bacterium Amoxyclav (30 mg/disc) Ampicillin (10 mg/disc) Oxacillin (1 mg/disc) Piperacillin/tazobactam (100/10 mg/disc)
I II III IV I II III IV I II III IV I II III IV
E. faecalis 62 67 70 74 52 68 69 72 59 67 71 72 53 66 71 69
S. aureus 71 77 82 79 68 74 76 77 66 67 76 74 61 79 75 78
A. baumannii 55 62 67 65 69 77 69 59 – – – – 47 61 64 55
Citrobacter sp. 52 58 61 65 54 59 62 71 – – – – 65 67 63 71
E. aerogenes 52 61 72 66 65 69 75 71 – – – – 65 80 81 76
E. coli 78 82 89 86 62 71 78 75 – – – – 51 57 58 55
K. oxytoca 58 62 70 68 74 79 81 80 – – – – 63 71 73 79
K. pneumoniae 54 67 76 73 74 79 83 79 – – – – 65 72 77 73
P. mirabilis 25 22 31 35 32 41 43 39 – – – – 27 31 35 35
P. vulgaris 42 38 41 44 34 39 48 44 – – – – 35 42 44 45
P. aeruginosa 68 70 75 74 55 54 67 65 – – – – 41 47 51 53
I: May–October 2011; II: November 2011–April 2012; III: May 2012–October 2012; IV: November 2012–April 2013; –: Not used.
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E. faecalis, 51–76% of 201 strains of S. aureus, 45–64% of 103
strains of A. baumannii, 27–76% of 68 strains of Citrobacter sp.,
52–72% of 98 strains of E. aerogenes, 75–88% of 253 strains of
E. coli, 53–78% of 60 strains of K. oxytoca, 54–74% of 146
strains of K. pneumoniae, 32–49% of 90 strains of P. mirabilis,
36–46% of 58 strains of P. vulgaris, and 77 to 49% of 98 strains
of P. aeruginosa (Table 6). All these three antibiotics were
almost equally resistant to the isolated UTI pathogens, con-
ﬁrming the consistence in the production of extended spectrum
b-lactamase (ESBL) by majority of isolates.Table 6
Percentage of resistance of all clinical isolated bacteria to three antibiotics o
Bacterium Cefepime (30 mg/disc) Cefta
I II III IV I
E. faecalis 62 67 70 73 57
S. aureus 54 67 76 72 51
A. baumannii 45 52 57 58 52
Citrobacter sp. 56 67 76 64 47
E. aerogenes 62 70 72 69 52
E. coli 75 82 88 86 79
K. oxytoca 53 58 61 68 67
K. pneumoniae 64 65 71 74 54
P. mirabilis 35 32 36 39 34
P. vulgaris 45 38 44 45 36
P. aeruginosa 65 71 77 77 49
I: May–October 2011; II: November 2011–April 2012; III: May 2012–OctoSimilarly, resistance-percent values of UTI-bacteria to anti-
biotics of the ﬂuoroquinolone group (gatiﬂoxacin, levoﬂoxacin,
ciproﬂoxacin and oﬂoxacin) in four 6-month phases were in
ranges, 51–76% of 157 strains of E. faecalis, 68–89% of 201
strains of S. aureus, 45–77% of 103 strains of A. baumannii, 47–
68% of 68 strains of Citrobacter sp., 47–81% of 98 strains of
E. aerogenes, 60–87% of 253 strains of E. coli, 44–65% of 60
strains of K. oxytoca, 58–81% of 146 strains of K. pneumoniae,
25–49% of 90 strains of P. mirabilis, 25–45% of 58 strains of
P. vulgaris, and 54–81% of 98 strains of P. aeruginosa
(Table 7). These antibiotics were resistant to UTI-pathogens inf cephalosporin group.
zidime (30 mg/disc) Ceftriaxone (30 mg/disc)
II III IV I II III IV
65 76 75 57 65 67 72
59 62 65 51 59 62 68
55 61 64 52 55 59 62
56 59 54 27 34 41 39
57 63 67 52 57 53 56
79 88 87 79 79 78 76
69 67 66 66 78 77 75
59 63 61 54 59 63 60
43 45 49 34 43 45 51
41 43 46 36 41 43 45
61 68 65 49 61 68 69
ber 2012; IV: November 2012–April 2013.
Table 7
Percentage of resistance of all clinical isolated bacteria to four antibiotics of ﬂuoroquinolone group.
Bacterium Gatiﬂoxacin (5 mg/disc) Levoﬂoxacin (5 mg/disc) Ciproﬂoxacin (5 mg/disc) Oﬂoxacin (5 mg/disc)
I II III IV I II III IV I II III IV I II III IV
E. faecalis 63 66 72 69 53 67 69 68 51 57 69 67 67 65 76 73
S. aureus 71 77 82 76 68 74 76 72 78 84 89 74 68 79 85 81
A. baumannii 48 54 59 59 69 77 59 54 45 52 61 77 62 67 74 71
Citrobacter sp. 53 58 61 68 47 52 56 54 56 61 65 57 56 54 56 61
E. aerogenes 47 52 51 57 65 69 75 74 72 78 81 69 52 61 63 59
E. coli 75 80 85 78 60 71 75 74 75 80 87 71 74 78 79 75
K. oxytoca 55 57 65 62 44 49 53 56 47 52 51 49 51 59 62 60
K. pneumoniae 58 62 70 68 74 79 81 80 63 71 73 79 60 68 72 72
P. mirabilis 25 31 29 33 37 45 46 43 35 38 45 45 31 45 47 49
P. vulgaris 32 38 41 45 34 39 42 41 25 34 37 39 35 37 43 41
P. aeruginosa 68 72 75 67 54 54 60 63 56 59 61 54 79 81 78 81
I: May–October 2011; II: November 2011–April 2012; III: May 2012–October 2012; IV: November 2012–April 2013.
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ﬂoxacin; the later one was newly introduced.
Lastly, detailed antibiograms of three stand-alone antibiotics,
co-trimoxazole, nitrofurantoin, and vancomycin were recorded.
Surprisingly, vancomycin 30 mg/disc was found resistance for
24 and 22% of strains of E. faecalis and S. aureus, respectively
(Table 8). Nine GN bacteria were tested for two stand-alone
antibiotics with resistance patterns as given: 45–64% of 103
strains of A. baumannii, 51–62% of 68 strains of Citrobacter sp.,
52–72% of 98 strains of E. aerogenes, 75–88% of 253 strains of
E. coli, 43–68% of 60 strains of K. oxytoca, 54–74% of 146
strains of K. pneumoniae, 32–49% of 90 strains of P. mirabilis,
36–46% of 58 strains of P. vulgaris, and 49–68% of 98 strains of
P. aeruginosa (Table 8).Table 8
Percentages of resistance of all clinical isolated bacteria to three stand-alone antibiotics.
Bacterium Co-trimoxazole (25 mg/disc) Nitrofurantoin (300 mg/disc) Vancomycin (30 mg/disc)
I II III IV I II III IV I II III IV
E. faecalis 62 67 70 73 – – – – 17 15 21 24
S. aureus 54 67 76 72 – – – – 11 19 22 18
A. baumannii 45 52 57 58 52 55 61 64 – – – –
Citrobacter sp. 51 59 62 60 47 52 51 57 – – – –
E. aerogenes 62 70 72 69 52 57 63 67 – – – –
E. coli 75 82 88 86 79 79 88 87 – – – –
K. oxytoca 43 51 53 59 59 61 65 68 – – – –
K. pneumoniae 64 65 71 74 54 59 63 61 – – – –
P. mirabilis 35 32 36 39 34 43 45 49 – – – –
P. vulgaris 45 38 44 45 36 41 43 46 – – – –
P. aeruginosa 65 71 77 77 49 61 68 65 – – – –
I: May–October 2011; II: November 2011–April 2012; III: May 2012–October 2012; IV: November 2012–April 2013; –: Not used.4. Discussion
In this surveillance, GP isolates S. aureus and E. faecalis
were vancomycin resistant, and all GN isolates were resistant to
nitrofurantoin and co-trimoxazole, the most preferred antibiotics
of empiric therapy for UTI in this zone. Prevalence of resistant-
strains of all pathogens increased in each 6-month period.
Further, b-lactam antibiotics were resistant in the order:
ampicillin > amoxyclav > piperacillin/tazobactam, for GN
bacteria. But with GP bacteria such the order was:
amoxyclav > ampicillin > oxacillin > piperacillin/tazobactam.
Antibiograms of 11 bacterial strains clearly demonstrated that all
those isolates were ﬂoridly MDR.In a multicenter study from India, involving 5 hospitals of
New Delhi, examining 531 samples from non-pregnant women
in OPDs, there were only 6 bacteria with prevalence-percent
values: E. coli (68%), Klebsiella sp. (16.9%), Proteus sp.
(5.5%), Enterobacter sp. (5.3%), Staphylococcus saprophyticus
(2.8%), Enterococcus (1.5%); GN bacteria were mostly sus-
ceptible to piperacillin/tazobactam (90%) and nitrofurantoin
(66%), but all of them were sensitive to meropenem (a carba-
penem)[36]. A recent report on childhood UTI from Jamshedpur,
India revealed that E. coli strains from urine samples were
increasingly resistant to penicillin and cephalosporin groups,
but those were susceptible to nitrofurantoin and levoﬂoxacin,
while cefoperazone-sulbactam was the most sensitive antibiotic
to other bacteria, Klebsiella, Proteus and Pseudomonas[37].A less recent epidemiological survey on uropathogens
causing uncomplicated cystitis was reported with 4264 female
patients from nine European countries and Brazil during 2003–
06 revealed that 10% E. coli isolates were resistant to three
different classes of antimicrobials with decreasing resistance
values, ampicillin (48.3%), trimethoprim sulfamethoxazole
(29.4%), nalidixic acid (18.6%). But, fosfomycin (98.1%),
mecillinam (95.8%) and nitrofurantoin (95.2%) were effective in
the control of E. coli. Further, P. mirabilis was recorded more
susceptible to b-lactams and less susceptible to other antibiotics.
K. pneumoniae strains were intrinsically resistant to ampicillin,
but comparatively less sensitive to mecillinam (88.8%), fosfo-
mycin (87.9%), cefuroxime (78.6%) and nitrofurantoin (17.7%),
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type[38].
An Israeli study, over a 10-year period recorded thatE. coliwas
the most prevalent and the most resistant pathogen, speciﬁcally
with resistant to amoxicillin-clavulanate, ceftriaxone, cephalothin
in uropathogens isolated from community[39]. Another study from
Israel described infection from the usually occurring bacteria
E. coli and Klebsiella sp., which were resistant to amoxicillin-
clavulanate (24%) and an initial empirical treatment with co-
trimoxazole and cephalexin was recorded as inadequate in
approximately one-third of the cases[40]. Less recently, from a
multi-locus sequence typing of important genetic lineage of
E. coli from UTI patients of North-west England, it was recorded
that E. coli strains with multi-resistance cause UTI infections and
subsequently bacteremia in community, eventually leading to
mortality[41]. Further, young Dutch males had E. coli, whereas
elderly males had P. aeruginosa as UTI infections; the
susceptibility to amoxicillin (63%) and trimethoprim (70%) was
low, while it was high towards ﬂuoroquinolones (91%) and
amoxicillin-clavulanate (90%)[42]. In an Italian study, collected
from 61273 urine samples over a 22-month period,
predominance of bacteria were with values as follows: E. coli
(67.6%), K. pneumoniae (8.8%), E. faecalis (6.3%), P. mirabilis
(5.2%), P. aeruginosa (2.5%). Females were more affected than
males. In this region, oral susceptibility to antibiotics were as
follows: fosfomycin (72.9%), trimethoprim/ sulfamethoxazole
(72.9%), ciproﬂoxacin (76.8%), ampicillin (48.0%), and
amoxicillin/ clavulanate (77.5%). The analysis on gender and
age related CA-UTI data revealed the presence of a similar set
of infection causing bacteria in almost urine samples, but Strep-
tococcus agalactiae and P. mirabilis were additionally present in
those from females[43]. A less recent American survey recorded
that cystitis and pyelonephritis account to 250000 individual
cases, and repeated cases of pyelonephritis in children caused
scaring of kidney, leading to the subsequent renal failure in an
adult stage[44]. Moreover, a recent American study revealed that
UTI E. coli infections were food borne, which had been a matter
of consternation both in paediatric as well as adult cases[45].
In a report from Thailand, it had been recorded that from CA-
UTI E. coli was the most predominant pathogen with ESBL-
producing activity and the isolates were resistant to gentamicin
(67%), cefotaxime (50%) and norﬂoxacin (50%)[46]. In a Chinese
report, it had been recorded that E. coli was the major pathogen
in community CA-UTI cases, followed by Enterococcus sp. in
Tianjin, China[47]. Most recently from Chongqing, China, the
prevalence of P aeruginosa as the determinative agent CA-
UTIs was recorded[48].
A report on uropathogens from Kenya with pulsed-ﬁeld gel
electrophoresis demonstrated that E. coli strains resistant to
ﬂuoroquinolones and other commonly used b-lactam antibiotics
had one of CTX-M-15 -b-lactamase or CMY-2 or AmpC type of
enzymes, and those caused major challenges in the management
of UTIs[49]. In a report from Madagascar of 903 pathogens from
urine samples of males and females, it was recorded that there
were 607 E. coli strains, 87 Klebsiella strains, 35 S. aureus
strains, 30 P. mirabilis strains; most of those were resistant to
amoxicillin, trimethoprim-sulfamethoxazole, ciproﬂoxacin, and
were limitedly resistant to ceftriaxone and fosfomycin; but all
those stains were sensitive to nitroxoline[5]. In a Ugandan study,
Staphylococcus (46.3%) and E. coli (39%) were reported as the
most commonly isolated UTI bacteria, and those were resistant
to co-trimoxazole (73.2%), nalidixic acid (52.4%) andamoxicillin (51.2%). Since majority of those isolates were sen-
sitive to gentamicin and amoxicillin-clavulanate, these antibi-
otics were suggested for the replacement of moribund drugs in
empiric therapy[7]. A Jordanian work recorded uropathogens,
Klebsiella sp., Proteus sp., Pseudomonas sp. and
S. saprophyticus occurring in the mention order in rural areas
as the predominant pathogens; the need of frequent revaluation
of prevalence of UTI bacteria was emphasized[50].
From the selected reports cited herein from different
geographic zones along with the data recorded herein, it could
be concluded that E. coli, followed by Klebsiella were the pre-
dominating UTI pathogens in most cases among GN bacteria,
and Staphylococcus was recorded as the frequently isolated GP
pathogen. All reported UTI bacteria were resistant to antibiotics
that were in use, routinely. Re-scheduling of empiric therapy in
treating UTI cases in most zones is required with an antibiotic
from a higher generation. Moreover, in this zone in India,
resistance of bacteria to the third generation cephalosporins and
imipenem (carbapenem) is of clinical consternation that would
be frequently met with any infection including the ones with
UTI. Further, due to the short length of urethra in females,
infection from fecal matter remains as a frequent possibility for
UTI. For the control, a potent antibiotic is always a dire ne-
cessity in primary care hospitals in community of any devel-
oping country. Obviously, periodic surveillance of pathogens is
an essential corollary in effective health management in any
country, as empiric therapy is a common/essential practice in
effective clinical management.
Conﬂict of interest statement
We declare that we have no conﬂict of interest.
Acknowledgements
This work was supported by the major research project no.
BT/PR8214/PBD/17/863/2013 on UTI causing bacteria from
Department of Biotechnology (DBT), Govt. of India, New
Delhi, awarded to RN Padhy. This work is a part of PhD thesis
of SN Rath a JRF in the DBT project, in Biotechnology of
S‘O’A University, Bhubaneswar. We are thankful to Prof. NK
Debata, Head of Microbiology Department, and Prof. DK Roy,
Medical Director, IMS and Sum Hospital, Bhubaneswar, for
extended facilities.
References
[1] Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ,
James D, et al. Community and hospital spread of Escherichia coli
producing CTX-M extended-spectrum b-lactamases in the UK.
J Antimicrob Chemother 2004; 54: 735-43.
[2] Dubey D, Rath S, Sahu MC, Pattnaik L, Debata NK, Padhy RN.
Surveillance of infection status of drug resistant Staphylococcus
aureus in an Indian teaching hospital. Asia Pacif J Trop Dis 2013;
3: 133-42.
[3] Mainous AG 3rd, Hueston WJ, Everett CJ, Diaz VA. Nasal car-
riage of Staphylococcus aureus and methicillin-resistant Staphy-
lococcus aureus in the United States, 2001–2002. Ann Fam Med
2006; 4: 132-7.
[4] Ben-Ami R, Rodrı´guez-Baño J, Arslan H, Pitout JD, Quentin C,
Calbo ES, et al. A multinational survey of risk factors for infection
with extended-spectrum beta-lactamase-producing enterobacte
riaceae in non-hospitalized patients. Clin Infect Dis 2009; 49: 682-
90.
Sibanarayan Rath, Rabindra N. Padhy/Journal of Acute Disease 2015; 4(3): 186–195194[5] Randrianirina F, Soares JL, Carod JF, Ratsima E, Thonnier V,
Combe P, et al. Antimicrobial resistance among uropathogens that
cause community-acquired urinary tract infections in Antananar-
ivo, Madagascar. J Antimicrob Chemother 2007; 59: 309-12.
[6] Arjunan M, Al-Salamah AA, Amuthan M. Prevalence and antibi-
otics susceptibility of uropathogens in patients from a rural envi-
ronment, Tamilnadu. Am J Infect Dis 2010; 6: 29-33.
[7] Odongo CO, Anywar DA, Luryamamoi K, Odongo P. Antibio-
grams from community-acquired uropathogens in Gulu, northern
Uganda-a cross-sectional study. BMC Infect Dis 2013; 13: 193.
[8] Ho PL, Yip KS, Chow KH, Lo JY, Que TL, Yuen KY. Antimi-
crobial resistance among uropathogens that cause acute uncom-
plicated cystitis in women in Hong Kong: a prospective
multicenter study in 2006 to 2008. Diagn Microbiol Infect Dis
2010; 66: 87-93.
[9] Sahu MC, Rath S, Dubey D, Debata NK, Padhy RN. Multidrug
resistance of Pseudomonas aeruginosa as known from surveillance
of nosocomial and community infections in an Indian teaching
hospital. J Publ Health 2012; 20: 413-23.
[10] Pilji D, Pilji D, Ahmetagi S, Ljuca F, Porobi H. Characteristics of
acute community-acquired urinary tract infections in adult hospi-
talised patients. Bosn J Basic Med Sci 2010; 10: 49-53.
[11] Ashley EA, Lubell Y, White NJ, Turner P. Antimicrobial suscep-
tibility of bacterial isolates from community acquired infections in
Sub-Saharan Africa and Asian low and middle income countries.
Trop Med Int Health 2011; 16: 1167-79.
[12] Valverde A, Grill F, Coque TM, Pintado V, Baquero F, Canto´n R,
et al. High rate of intestinal colonization with extended spectrum
beta-lactamase producing organisms in household contacts of
infected community patients. J Clin Microbiol 2008; 46: 2796-9.
[13] Khan AU, Raffaele Z. Multidrug resistance: a global concern.
USA: Bentham Publishers; 2012.
[14] Stranieri G, Zampogna S, Ielapi V, Deﬁlippo RG, Deﬁlippo V,
Cristofaro G, et al. Ceﬁxime for the prophylaxis of urinary tract
infections in children with malformative uropathies: an open study.
Eur Rev Med Pharmacol Sci 2003; 7: 57-64.
[15] Pennington JE, Reynolds HY, Carbone PP. Pseudomonas pneu-
monia: a retrospective study of 36 cases. Am J Med 1973; 55: 155-
60.
[16] Arenstein AW, Cross SA. Local and disseminated disease caused
by Pseudomonas aeruginosa. In: Mario C, Mauro B, Herman F,
editors. Pseudomonas aeruginosa as an opportunistic pathogen.
New York: Plenum; 1993, p. 223-244.
[17] Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N,
Antonopoulou A, Tsaganos T, Kanellakopoulou K, et al. Multidrug
resistance to antimicrobials as a predominant factor inﬂuencing
patient survival. Int J Antimicrob Agents 2006; 27: 476-81.
[18] Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for
preventing recurrent urinary tract infection in postmenopausal
women. Cochrane Database Syst Rev 2008; http://dx.doi.org/
10.1002/14651858.CD005131.pub2.
[19] Narciso A, Fonseca F, Cerqueira SA, Duarte A. Antibiotic sus-
ceptibility of bacteria responsible for uncomplicated cystitis:
comparative study of isolates from 2008 and 2010. Acta Urol 2011;
1: 16-21.
[20] Su C. Female lower urinary tract infection. JTUA 2008; 19: 12-20.
[21] Sheerin NS. Urinary tract infection. Medicine 2011; 39: 384-9.
[22] Moura A, Nicolau A, Hooton T, Azeredo J. Antibiotherapy and
pathogenesis of uncomplicated UTI: difﬁcult relationships. J Appl
Microbiol 2009; 106: 1779-91.
[23] Sh Dreshaj, Doda-Ejupi T, Tolaj IQ, Mustafa A, Kabashi S,
Shala N, et al. Clinical role of ceﬁxime in community-acquired
infections. Prilozi 2011; 32: 143-55.
[24] Limbago B, Fosheim GE, Schoonover V, Crane CE, Nadle J,
Petit S, et al. Characterization of methicillin-resistant Staphylo-
coccus aureus isolates collected in 2005 and 2006 from patients
with invasive disease: a population-based analysis. J Clin Micro-
biol 2009; 47: 1344-51.
[25] McGeer A, Campbell B, Emori TG, Hierholzer WJ, Jackson MM,
Nicolle LE, et al. Deﬁnitions of infection for surveillance in long-
term care facilities. Am J Infect Control 1991; 19: 1-7.[26] Kaye D. Urinary tract infections in the elderly. Bull N. Y Acad Med
1980; 56: 209-20.
[27] Kunin CM, Chin QF, Chambers S. Morbidity and mortality asso-
ciated with indwelling catheters in elderly patients in a nursing
home—confounding due to the presence of associated diseases.
J Am Geriatr Soc 1987; 35: 1001-6.
[28] Nicolle LE, Mayhew WJ, Bryan L. Prospective randomized com-
parison of therapy and no therapy for asymptomatic bacteriuria in
institutionalized elderly women. Am J Med 1987; 83: 27-33.
[29] Lane DR, Takhar SS. Diagnosis and management of urinary tract
infection and pyelonephritis. Emerg Med Clin North Am 2011; 29:
539-52.
[30] D'Andrea MM, Venturelli C, Giani T, Arena F, Conte V,
Bresciani P, et al. Persistent carriage and infection by multidrug-
resistant Escherichia coli ST405 producing NDM-1 carbapene-
mase: report on the ﬁrst Italian cases. J Clin Microbiol 2011; 49:
2755-8.
[31] Zimmet P, Alberti KG, Shaw J. Global and societal implications of
the diabetes epidemic. Nature 2001; 414: 782-7.
[32] Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ,
Paciorek CJ, et al. National, regional, and global trends in fasting
plasma glucose and diabetes prevalence since 1980: systematic
analysis of health examination surveys and epidemiological studies
with 370 country-years and 2$7 million participants. Lancet 2011;
378: 31-40.
[33] Thomsen RW, Mor A. Diabetes and risk of community-acquired
respiratory tract infections, urinary tract infections, and bacter-
emia. Open Infect Dis J 2012; 6: 27-39.
[34] Forbes BA, Sahm DF, Weissfeld AS, editors. Bailey and Scott's
diagnostic microbiology. 12th ed. St. Louis, USA: Mosby Elsevier;
2007.
[35] Clinical and Laboratory Standards Institute. Performance standard
for antimicrobial susceptibility testing: twenty-ﬁrst informational
supplement. Wayne, PA: CLSI; 2011.
[36] Kothari A, Sagar V. Antibiotic resistance in pathogens causing
community-acquired urinary tract infections in India: a multicenter
study. J Infect Dev Ctries 2008; 2: 354-8.
[37] Sharan R, Kumar D, Mukherjee B. Bacteriology and antibiotic
resistance pattern in community acquired urinary tract infection.
Indian Pediatr 2013; 50: 707.
[38] Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L. The
ARSEC study: an international survey on the antimicrobial resis-
tance of pathogens involved in uncomplicated urinary tract in-
fections. Int J Antimicrob Agents 2009; 34: 407-13.
[39] Rock W, Colodner R, Chazan B, Elias M, Raz R. Ten year's sur-
veillance of antimicrobial susceptibility of community-acquired
Escherichia coli and other uropathogens in Northern Israel
(1995–2005). Isr Med Assoc J 2007; 9: 803-5.
[40] Prais D, Straussberg R, Avitzur Y, Nussinovitch M, Harel L,
Amir J. Bacterial susceptibility to oral antibiotics in
community acquired urinary tract infection. Arch Dis Child
2003; 88: 215-8.
[41] Lau SH, Reddy S, Cheesbrough J, Bolton FJ, Willshaw G,
Cheasty T, et al. Major uropathogenic Escherichia coli strain iso-
lated in the north-west of England identiﬁed by multi-locus
sequence typing. J Clin Microbiol 2008; 46: 1076-80.
[42] Koeijers JJ, Verbon A, Kessels AGH, Bartelds A, Donker G,
Nys S, et al. Urinary tract infection in male general practice pa-
tients: uropathogens and antibiotic susceptibility. Urology 2010;
76: 336-40.
[43] Magliano E, Grazioli V, Deﬂorio L, Leuci AI, Mattina R,
Romano P, et al. Gender and age-dependent etiology of
community-acquired urinary tract infections. ScientiﬁcWorldJour-
nal 2012; http://dx.doi.org/10.1100/2012/349597.
[44] Orellana P, Baquedano P, Rangarajan V, Zhao JH, Eng ND,
Fettich J, et al. Relationship between acute pyelonephritis, renal
scarring, and vesicoureteral reﬂux: results of a coordinated research
project. Pediatr Nephrol 2004; 19: 1122-6.
[45] Nordstrom L, Liu CM, Price LB. Foodborne urinary tract in-
fections: a new paradigm for antimicrobial-resistant food borne
illness. Front Microbiol 2013; 4: 29.
Sibanarayan Rath, Rabindra N. Padhy/Journal of Acute Disease 2015; 4(3): 186–195 195[46] Tunyapanit W, Pruekprasert P. Extended-spectrum beta-lactamases
in Escherichia coli isolated from patients with community-acquired
urinary tract infection at Songklanagarind hospital, Thailand.
J Infect Dis Antimicrob Agents 2006; 2: 51-6.
[47] Fan SY, Zhang BL, Wang WH, Zhang X. [Bacterial pathogens and
resistance patterns in community acquired pediatric urinary tract
infection: experience of 152 cases]. Zhongguo Dang Dai Er Ke Za
Zhi 2006; 8: 115-7. Chinese.
[48] Fu XH, Zhou W, Zhang XM, Yin YB, Jing CM, Liu L, et al.
[Clinical analysis of 22 cases community-acquired Pseudomonasaeruginosa urinary tract infection]. Zhonghua Er Ke Za Zhi 2013;
51: 298-301. Chinese.
[49] Kariuki S, Revathi G, Corkill J, Kiiru J, Mwituria J, Mirza N, et al.
Escherichia coli from community-acquired urinary tract infections
resistant to ﬂuoroquinolones and extended-spectrum beta-lactams.
J Infect Dev Ctries 2007; 1: 257-62.
[50] Nimri L. Community-acquired urinary tract infections in a rural
area in jordan: predominant uropathogens, and their antimicrobial
resistance. Webmed Cent Microbiol 2010; 1: 1-10.
